Vandetanib successfully controls medullary thyroid cancer-related Cushing syndrome in an adolescent patient. [electronic resource]
Producer: 20150112Description: 3055-9 p. digitalISSN:- 1945-7197
- Adolescent
- Adrenocorticotropic Hormone -- metabolism
- Carcinoma, Neuroendocrine
- Clinical Trials, Phase I as Topic
- Clinical Trials, Phase II as Topic
- Cushing Syndrome -- etiology
- Humans
- Male
- Multiple Endocrine Neoplasia Type 2b -- complications
- Neoplasms, Second Primary -- complications
- Piperidines -- therapeutic use
- Protein-Tyrosine Kinases -- antagonists & inhibitors
- Quinazolines -- therapeutic use
- Thyroid Neoplasms -- complications
No physical items for this record
Publication Type: Case Reports; Journal Article; Research Support, N.I.H., Intramural
There are no comments on this title.
Log in to your account to post a comment.